Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study

NCT00317200 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT00317200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
November 30, 2007
Enrollment
34 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer